clinical trial · NCT06257355
Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects With Corneal Scars
Claris Biotherapeutics, Inc.·phase1·recruiting·n = 20
Corneal ScarCSB-001 Ophthalmic Solution 0.1%
brief summary
This study will enroll subjects with recently formed corneal scars that resulted from a corneal insult presenting and diagnosed within the past approximately 30 days and not less than approximately 7 days. All subjects will be assigned to CSB-001 investigational treatment on Day 1. All subjects will dose with CSB-001 four times daily or three times daily starting on Day 1 and continue until Day 14. Subjects with a resolved scar at Day 7 will discontinue dosing and return to the clinic on Day 14. Subjects will return on Days 21, 28, 56, and Month 3 for safety and efficacy assessments.
started
Feb 5, 2024
primary completion
Jun 30, 2027
completion
Jun 30, 2027
last updated
Apr 7, 2026
official title
A Two-Arm Open-Label Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects With Corneal Scars
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol